<?xml version='1.0' encoding='utf-8'?>
<document id="22620695"><sentence text="Evaluation of the biliary and brain distribution of technetium Tc 99m sestamibi in healthy dogs with the ABCB1 wildtype genotype before and after treatment with spinosad." /><sentence text="To determine whether the reported drug-drug interaction between the flea medication spinosad and ivermectin is attributable to inhibition of P-glycoprotein by spinosad"><entity charOffset="97-107" id="DDI-PubMed.22620695.s2.e0" text="ivermectin" /></sentence><sentence text="" /><sentence text="6 healthy adult dogs with the ABCB1 wildtype genotype" /><sentence text="" /><sentence text="The study was conducted as a prospective, masked, randomized crossover design" /><sentence text=" Six dogs were allocated to 2 groups; each dog served as its own control animal" /><sentence text=" Dogs in one of the groups received spinosad at the manufacturer's recommended dose; the other group received no treatment" /><sentence text=" Forty-eight hours later, scintigraphic imaging of the head and abdomen were performed with the radiolabeled P-glycoprotein substrate methoxy-isobutyl-isonitrile (sestamibi) in both groups of dogs"><entity charOffset="134-161" id="DDI-PubMed.22620695.s9.e0" text="methoxy-isobutyl-isonitrile" /><entity charOffset="163-172" id="DDI-PubMed.22620695.s9.e1" text="sestamibi" /><pair ddi="false" e1="DDI-PubMed.22620695.s9.e0" e2="DDI-PubMed.22620695.s9.e0" /><pair ddi="false" e1="DDI-PubMed.22620695.s9.e0" e2="DDI-PubMed.22620695.s9.e1" /></sentence><sentence text=" After a washout period of 60 days, the dogs in each group received the alternate treatment, and scintigraphic imaging again was performed 48 hours later" /><sentence text=" Gallbladder-to-liver and brain-to-neck musculature ratios of technetium Tc 99m sestamibi were calculated for each dog and compared between treatments" /><sentence text="" /><sentence text="No significant differences in gallbladder-to-liver or brain-to-neck musculature ratios were found between treatments" /><sentence text="" /><sentence text="Results provided evidence that spinosad did not inhibit P-glycoprotein function 48 hours after spinosad was administered at the manufacturer's recommended dose" /><sentence text=" Further investigations will be necessary to elucidate the mechanism of the reported toxic interaction between spinosad and ivermectin"><entity charOffset="124-134" id="DDI-PubMed.22620695.s16.e0" text="ivermectin" /></sentence><sentence text="" /></document>